Quad-agonist peptides (GLP-1/GIP/glucagon/GCG analogs): In preclinical development, these add galanin or other receptor targets to the triple-agonist backbone
This can contribute to better blood sugar control, especially in individuals with type 2 diabetes
Step three: the washout period (days 1 through 25-30) During this period, focus entirely on maintaining your results without pharmaceutical support
Weight loss is an important factor in type 2 diabetes management and is often complicated by diabetic agents that promote weight gain (i.e., sulfonylureas, thiazolidinediones (TZDs), insulin)
Dr Koul added that Indian patients are becoming less brand-conscious, supported by initiatives like the Pradhan Mantri Jan Aushadhi Kendra
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients